| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
ERK2 (extracellular signal-regulated kinase 2). (R)-VX-11e is an ERK2 inhibitor. It binds to the ATP-binding pocket of ERK2, blocking its kinase activity and preventing phosphorylation of downstream targets involved in cell proliferation, survival, differentiation, and migration.
|
|---|---|
| ln Vitro |
(R)-VX-11e is a selective ERK2 inhibitor with demonstrated antitumor activity in cellular and animal models of various cancers. The specific IC50 for (R)-VX-11e is not reported; however, it is described as a potent and selective ERK2 inhibitor. It is the (R)-enantiomer of VX-11e, which is a well-characterized ERK2 inhibitor with low nM potency. The compound is useful for validating ERK2 as a therapeutic target in MAPK pathway-driven cancers.
|
| ln Vivo |
(R)-VX-11e has demonstrated antitumor activity in cellular and animal models of various cancers. It is utilized in cancer research to study MAPK/ERK pathway signaling. As the (R)-enantiomer of VX-11e, it is expected to share the in vivo efficacy profile of VX-11e, which includes inhibition of tumor growth in xenograft models of BRAF-mutant and KRAS-mutant cancers. Specific in vivo data for the (R)-enantiomer are not provided.
|
| Enzyme Assay |
Cell-free ERK2 kinase activity assays are performed using recombinant human ERK2 enzyme. The enzyme is incubated with a peptide substrate (e.g., myelin basic protein or an ERK-specific peptide) and ATP in the presence of increasing concentrations of (R)-VX-11e (0.001-10,000 nM) in assay buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM DTT). After 30-60 min at 30degC, the reaction is terminated, and IC50 is determined by measuring phosphorylated substrate via luminescence (ADP-Glo) or 33P incorporation. Selectivity is assessed against other MAPK family members and other kinases.
|
| Cell Assay |
BRAF-mutant (e.g., A375, WM266.4) or KRAS-mutant (e.g., HCT116, A549) cancer cell lines are seeded in 96-well plates and treated with (R)-VX-11e at various concentrations (0.1-10,000 nM) for 48-72 hours. Cell viability is assessed by MTT or CellTiter-Glo assay. ERK2-mediated phosphorylation of downstream targets (e.g., pRSK, pCREB, pELK1) is measured by Western blot or phospho-flow cytometry. Apoptosis is measured by Annexin V/PI staining and flow cytometry. Colony formation assays are performed over 7-14 days. IC50 for growth inhibition is determined. The effect of (R)-VX-11e on downstream signaling is confirmed by assessing pERK substrate phosphorylation.
|
| Animal Protocol |
For in vivo studies, (R)-VX-11e is formulated in a suitable vehicle (e.g., 0.5% methylcellulose, 5% DMSO + 45% PEG300 + 50% water, or 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline). Dosing: oral gavage at 10-100 mg/kg daily. Efficacy studies: female BALB/c nude mice with subcutaneous xenografts of BRAF-mutant or KRAS-mutant cancer cell lines. Tumor volumes are measured with calipers every 2-3 days. Body weight is monitored. At study termination, tumors are excised for pERK measurement by Western blot or immunohistochemistry. Pharmacodynamic studies: blood and tumor samples are collected at various time points post-dose for PK/PD analysis. No specific published data for (R)-VX-11e are provided, but VX-11e has shown in vivo efficacy.
|
| ADME/Pharmacokinetics |
No specific PK data are reported for (R)-VX-11e. The molecular weight is 500.35 (C24H20Cl2FN5O2). CAS 1680187-43-2. Formula: C24H20Cl2FN5O2. The compound is described as having antitumor activity in animal models, indicating it has favorable PK properties (oral bioavailability, acceptable half-life). Solubility: DMSO (10-50 mg/mL). Storage: -20degC. PK parameters (t1/2, Cmax, AUC, oral bioavailability) have not been characterized for the (R)-enantiomer specifically.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for (R)-VX-11e. As an ERK2 inhibitor, potential toxicities include effects on normal tissues with high MAPK pathway activity (e.g., gastrointestinal epithelium, skin). VX-11e, the parent compound, has been shown to be generally well-tolerated in preclinical studies. Standard safety assessments (hERG, Ames, repeat-dose toxicity) have not been published for (R)-VX-11e. No clinical trials have been conducted. Not FDA-approved. For research use only.
|
| References |
[1]. Vanderpool D, et al. Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors. Anal Biochem. 2015 Mar 15;473:46-52.
|
| Additional Infomation |
Other information: (R)-VX-11e (CAS 1680187-43-2) is a research compound, not FDA-approved. It is the (R)-enantiomer of the potent and selective ERK2 inhibitor VX-11e. It is used in cancer research to study the MAPK/ERK pathway, particularly in BRAF- and KRAS-mutant cancers. It is a valuable enantiomer for stereospecificity studies of ERK2 inhibition. Purity ≥98%. For research use only.
|
| Molecular Formula |
C24H20CL2FN5O2
|
|---|---|
| Molecular Weight |
500.35
|
| Exact Mass |
499.097
|
| CAS # |
1680187-43-2
|
| Related CAS # |
VX-11e;896720-20-0
|
| PubChem CID |
44814860
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
679
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CN=C(N=C1C2=CNC(=C2)C(=O)N[C@@H](CO)C3=CC(=CC=C3)Cl)NC4=C(C=C(C=C4)F)Cl
|
| InChi Key |
WUTVMXLIGHTZJC-NRFANRHFSA-N
|
| InChi Code |
InChI=1S/C24H20Cl2FN5O2/c1-13-10-29-24(31-19-6-5-17(27)9-18(19)26)32-22(13)15-8-20(28-11-15)23(34)30-21(12-33)14-3-2-4-16(25)7-14/h2-11,21,28,33H,12H2,1H3,(H,30,34)(H,29,31,32)/t21-/m0/s1
|
| Chemical Name |
4-[2-(2-chloro-4-fluoroanilino)-5-methylpyrimidin-4-yl]-N-[(1R)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9986 mL | 9.9930 mL | 19.9860 mL | |
| 5 mM | 0.3997 mL | 1.9986 mL | 3.9972 mL | |
| 10 mM | 0.1999 mL | 0.9993 mL | 1.9986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
